Repurposing Riluzole for Augmenting Brain-Derived Neuropathic Factor (BDNF) Levels and Cognitive Function in Breast Cancer Patients Experiencing Cancer-Related Cognitive Impairment: An Interventional Pilot Clinical Trial
Details
This is a phase 2a, randomized, double-blinded, placebo-controlled pilot clinical trial determining the impact of riluzole therapy on circulating brain derived neuropathic factor (BDNF) levels of breast cancer survivors with cancer related cognitive impairment.
Eligibility
You can join if...
Please note this may not be a complete list of eligibility criteria. We have included a few examples of study criteria to help you better understand how your eligibility in the study will be determined; your study team will go through the study eligibility criteria with you to verify if you qualify for participation in this study.
Inclusion Requirements
• Diagnosed with breast cancer
• Past exposure to chemotherapy, radiotherapy, surgery, and/or other breast cancer interventions
• ≥18 years of age
• Perceived that cognitive function has worsened since cancer diagnosis and/or beginning of cancer treatment
• Able to provide informed consent
• Must agree to complete and able to complete the questionnaires and computerized assessments
Exclusion Requirements
• Presence of brain metastases
• Unwilling to undergo neuropsychological assessments necessary for the study
• Breastfeeding, pregnant or are planning get pregnant during the study period
• History of or suspected hypersensitivity to riluzole or to any of its inactive ingredients
• Patients taking or planning to take medications/substances with potential drug-drug interactions
• Hepatic impairment: Patients with measured serum transaminases 3 times greater than upper limit of normal